Navigation Links
InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Date:9/16/2009

Optiferrin shown to provide superior performance in cell culture and addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Fort Collins, CO (PRWEB) September 16, 2009 -- InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance.

"Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin," said Scott Deeter, President & CEO of InVitria.

"Transferrin is nature's way to deliver iron in a non-toxic manner," said Dr. Steve Pettit, InVitria's Director of Cell Culture Development. "Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customer's concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media," said Dr. Pettit.

Optiferrin is a complimentary product to InVitria's other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria's product line, contact us at info(at)InVitria(dot)com or call 1-800-916-8311.

# # #

Read the full story at http://www.prweb.com/releases/Optiferrin/recombinanttransferrin/prweb2895654.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria Cell Culture Product Line to Headline PEACe
2. InVitria Sponsors ESACT 2009 in Dublin, Ireland
3. InVitria to Present at BIO 2009 International Convention in Atlanta
4. InVitria Reveals Technology to Optimize Hybridoma Production Performance
5. InVitria Headlines Sponsorship of WilBio's Waterside Conference
6. InVitria Announces Launch of Recombinant Albumin for Diagnostics
7. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
8. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
9. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
10. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
11. InVitria to Present at WilBio's International Cell Engineering Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 2017 , ... SignatureCare Emergency Center is looking to award their ... to a deserving student. Get your applications in now as the deadline is ... Castillo who is a nursing student at Prairie View A&M University with a 3.45 ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... Oakland, California effectively destroyed the construction site and threatened numerous homes and businesses ... 7th article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection ...
(Date:7/24/2017)... CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... and financial organizations, today announced it has partnered with WALLIX to expand ... Special Publication 800-171 . , There are a number of ways to address the ...
(Date:7/24/2017)... California (PRWEB) , ... July 24, 2017 , ... ... of autologous fat (adipose) transfer systems announces the issuance of United States Patent ... patent) for its adipose filtration technology. The '398 and '324 patents cover ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... sleep management solution focused on delivering end-to-end sleep health care at scale, ... Recent literature shows that adherence rates for positive airway pressure (PAP) therapy, the ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... and EDMONTON, Alberta , July ... and the University of Alberta in ... in Nature,s partner journal, Schizophrenia 1 , demonstrating ... instances of schizophrenia with 74% accuracy. This retrospective ... of specific symptoms in schizophrenia patients with significant ...
(Date:7/21/2017)... , July 21, 2017  Endo International plc (NASDAQ: ... a comprehensive review of its manufacturing network, the Company ... distribution facilities in Huntsville, Alabama . ... place over the next 12 to 18 months. The ... by declining volumes of commoditized products and these restructuring ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) ... Gavras , M.D., following today,s Institute for Clinical and Economic ... on the effectiveness and value of abuse-deterrent formulations (ADF) ... the policy roundtable at the meeting. ... a material cost benefit to the use of abuse-deterrent formulations ...
Breaking Medicine Technology: